CLAIMS

What is claimed:

1. A multispecific molecule comprising a first binding domain and a second binding domain, wherein the first binding domain binds immunoglobulin, and the second binding domain binds a recycling target.

2. The multispecific molecule of Claim 1, wherein the first binding domain is an scFv, Fv, scFab, Fab', or Fab and the second binding domain is an scFv, Fv, scFab, Fab', or Fab.

3. The multispecific molecule of Claim 1 or Claim 2, wherein said first binding domain and/or second binding domain is an scFv.

4. The multispecific molecule of any one of Claims 1-3, wherein the first binding domain and the second binding domain are each an scFv.

5. The multispecific molecule of Claim 1 or Claim 2, wherein said first binding domain and/or second binding domain is an scFab.

6. The multispecific molecule of any one of Claims 1, 2, and 5, wherein the first binding domain and the second binding domain are each an scFab.

7. The multispecific molecule of Claim 1 or Claim 2, wherein said first binding domain and/or second binding domain is a Fab.

8. The multispecific molecule of any one of Claims 1, 2, and 7, wherein the first binding domain and the second binding domain are each a Fab.

9. The multispecific molecule of Claim 1 or Claim 2, wherein said first binding domain is an scFv and the second binding domain is a Fab.

10. The multispecific molecule of Claim 1 or Claim 2, wherein said first binding domain is an scFv and the second binding domain is a scFab.

11. The multispecific molecule of Claim 1 or Claim 2, wherein said first binding domain is a Fab and the second binding domain is an scFv.

12. The multispecific molecule of Claim 1 or Claim 2, wherein said first binding domain is a scFab and the second binding domain is an scFv.

13. The multispecific molecule of Claim 1 or Claim 2, wherein said first binding domain is a Fab and the second binding domain is an scFab.

14. The multispecific molecule of Claim 1 or Claim 2, wherein said first binding domain is a scFab and the second binding domain is a Fab.

15. The multispecific molecule of any one of Claims 1-14, wherein the first binding domain and second binding domain are connected via a linker.

16. The multispecific molecule of Claim 15, wherein the linker is a polypeptide linker.

17. The multispecific molecule of Claim 15, wherein the linker is a SG_4S linker.

18. The multispecific molecule of Claim 15, wherein the linker comprises a sequence selected from the group consisting of $(Gly_3Ser)_3$ (SEQ ID NO: 53), $(Gly_4Ser)_3$ (SEQ ID NO: 54), $(Gly_3Ser)_4$ (SEQ ID NO: 55), $(Gly_4Ser)_4$ (SEQ ID NO: 56), $(Gly_3Ser)_5$ (SEQ ID NO: 57), $(Gly_4Ser)_5$ (SEQ ID NO: 58), $(Gly_3Ser)_6$ (SEQ ID NO: 59), $(Gly_4Ser)_6$ (SEQ ID NO: 60), GSADDAKKDAAKKDAAKKDDAKKDDAGS (SEQ ID NO: 61), GSADDAKKDAAKKDAAKKDDAKKDDAKKDAGS (SEQ ID NO: 62), $(Gly_3Gln)_2$ (SEQ ID NO: 63), $(Gly_4Gln)_2$ (SEQ ID NO: 64), $(Gly_3Gln)_3$ (SEQ ID NO: 65), $(Gly_4Gln)_3$ (SEQ ID NO: 66), $(Gly_3Gln)_4$ (SEQ ID NO: 67), $(Gly_4Gln)_4$ (SEQ ID NO: 68), $(Gly_3Gln)_5$ (SEQ ID NO: 69), $(Gly_4Gln)_5$ (SEQ ID NO: 70), $(Gly_3Gln)_6$ (SEQ ID NO: 71), $(Gly_4Gln)_6$ (SEQ ID NO: 72), $(Gly_3Ser)_2$ (SEQ ID NO: 73), and $(Gly_4Ser)_2$ (SEQ ID NO: 74).

19. The multispecific molecule of any one of Claims 1-18, wherein the immunoglobulin bound by the first domain is IgG, IgA, IgE, IgD, or IgM.

20. The multispecific molecule of Claim 19, wherein the immunoglobulin is IgG or IgA.

21. The multispecific molecule of any one of Claims 1-20, wherein the immunoglobulin is expressed on a plasma cell or on a B cell.

22. The multispecific molecule of any one of Claims 1-20, wherein the immunoglobulin is circulating in blood.

23. The multispecific molecule of any one of Claims 1-22, wherein the recycling target is ASGR1.

24. The multispecific molecule of any one of Claims 1-23, wherein the multispecific molecule depletes at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of immunoglobulin in vivo.

25. The multispecific molecule of Claim 24, wherein the multispecific molecule depletes at least 70% of immunoglobulin.

26. The multispecific molecule of any one of Claims 1-25, wherein the multispecific molecule depletes immunoglobulin in a human, cynomolgus monkey, or mouse.

27. The multispecific molecule of any one of Claims 24-26, wherein the immunoglobulin is depleted in less than 72 hours.

28. The multispecific molecule of any one of Claims 1-27, wherein the multispecific molecule dissociates from the immunoglobulin in an endosome of a cell that expresses the recycling target.

29. The multispecific molecule of Claim 28, wherein the multispecific molecule remains bound to the recycling target in the endosome and is recycled to the cell surface.

30. The multispecific molecule of any one of Claims 1-27, wherein the multispecific molecule dissociates from the recycling target in an endosome of a cell that expresses the recycling target.

31. The multispecific molecule of any one of Claims 1-30 for use in therapy.

32. Use of a multispecific molecule of any one of Claims 1-30 for the manufacture of a medicament for the treatment of autoantibody-induced disease.

33. The use of Claim 32, wherein the autoantibody-induced disease is selected from the group consisting of myasthenia gravis, Guillain-Barre syndrome, epilepsy, autoimmune limbic encephalitis, spinal cord injury, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection, neuromyotonia, morvan syndrome, multiple sclerosis, pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, epidermosysis bullosa acquisita, pemphigoig gestationis, mucous membrane pemphigoid, licen sclerosus, antiphospholipid syndrome, relapsing polychondritis, autoimmune anemia, idiopathic trombocytic purpura, autoimmune Grave’s disease, dilated cardiomyopathy, vasculitis, goodpasture’s syndrome, idiopathic membranous nephropathy, rheumatoid arthritis, and systemic lupus erythematosus.